Moreover, the study by Wongsurawat et al. (2020) employed the nCATS to simultaneously evaluate dehydrogenase (IDH) gene mutation status and the methylation level of O6-methylguanine-DNA methyltransferase (MGMT) promoter in four human glioblastoma (GBM) cell lines and eight fresh human brain tumor samples. This evidence concerns the gene IDH2 and brain neoplasm.